Certara (NASDAQ:CERT) Reaches New 12-Month Low – Here’s Why

Certara, Inc. (NASDAQ:CERT) shares hit a new 52-week low during mid-day trading on Monday . The stock traded as low as $7.10 and last traded at $7.0960, with a volume of 49251 shares changing hands. The stock had previously closed at $7.23.

Analyst Ratings Changes

CERT has been the subject of several analyst reports. Barclays cut their price target on Certara from $14.00 to $13.00 and set an “overweight” rating for the company in a report on Monday, December 15th. Stephens lowered their price objective on Certara from $15.00 to $12.00 and set an “overweight” rating for the company in a research report on Friday, December 12th. KeyCorp reduced their target price on Certara from $13.00 to $12.00 and set an “overweight” rating on the stock in a research report on Thursday, January 8th. Leerink Partners raised Certara from a “market perform” rating to an “outperform” rating and set a $13.00 price target on the stock in a research note on Tuesday, January 6th. Finally, Rothschild & Co Redburn set a $10.00 price target on Certara in a report on Friday, November 21st. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $12.82.

Certara Trading Down 2.4%

The firm’s 50 day simple moving average is $9.06 and its 200-day simple moving average is $10.28. The company has a quick ratio of 2.09, a current ratio of 2.09 and a debt-to-equity ratio of 0.27. The company has a market capitalization of $1.12 billion, a PE ratio of 100.21 and a beta of 1.47.

Certara (NASDAQ:CERT) last released its quarterly earnings data on Thursday, November 6th. The company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.11 by $0.03. The company had revenue of $104.62 million for the quarter, compared to analyst estimates of $104.53 million. Certara had a return on equity of 5.18% and a net margin of 2.62%.During the same period last year, the company posted $0.13 earnings per share. As a group, equities research analysts anticipate that Certara, Inc. will post 0.28 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. First Horizon Corp acquired a new stake in Certara during the 3rd quarter valued at $30,000. Versant Capital Management Inc boosted its position in Certara by 66.7% in the 3rd quarter. Versant Capital Management Inc now owns 2,881 shares of the company’s stock valued at $35,000 after buying an additional 1,153 shares during the last quarter. Osaic Holdings Inc. grew its stake in shares of Certara by 50.7% during the second quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock valued at $41,000 after acquiring an additional 1,175 shares in the last quarter. Elevation Point Wealth Partners LLC purchased a new stake in shares of Certara during the second quarter worth about $59,000. Finally, Global Retirement Partners LLC increased its position in shares of Certara by 45.0% during the third quarter. Global Retirement Partners LLC now owns 5,636 shares of the company’s stock worth $69,000 after acquiring an additional 1,749 shares during the last quarter. 73.96% of the stock is currently owned by hedge funds and other institutional investors.

About Certara

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.